Applied Integrin Sciences Inc discovers, develops, and commercializes protein drug therapies for cancer treatments that reduce solid tumor growth and progression and improve patient survival and quality of life. The company's founder-Scientists discovered a proprietary drug discovery platform for producing novel protein therapeutics modulating specific Integrin receptors known to be involved in cancer growth, progression, and metastasis. These recombinant proteins affect primary tumors, tumor vasculature, and metastatic Foci involved in Cancer, as in the Metastatic Breast Cancer cell shown in the image above. The novel mechanism of action of Vicrostatin, the company's first candidate, and ADMol, one of the twenty-three proprietary ADAM-derived Disintegrin drug candidates, produces equally substantial reduced tumor progression in six aggessive metastatic tumors in vivo: Triple Negative Breast Cancer, Primary Prostate Cancer, Prostate Cancer Bone Metastasis, Ovarian Cancer, Melanoma, and Glioblastoma.
